
A new drug, loberamisal, has shown promising results in improving functional recovery rates for patients who have suffered an ischaemic stroke. The phase III clinical trial results, published in JAMA in September 2026, revealed that the drug increased the likelihood of a full recovery to 69.7% when administered within 48 hours of the stroke.
Dr. Suya Li of Beijing Tiantan Hospital, Capital Medical University, presented the findings at the American Stroke Association’s International Stroke Conference in 2026. The trial, conducted across 32 hospitals in China from July 2024 to April 2025, involved a double-blind, placebo-controlled design.
Loberamisal is the first neuroprotective drug to demonstrate a statistically significant benefit for mild to moderate ischaemic stroke patients. It reduced the number of patients with even slight disabilities by 12%, increasing the odds of a full recovery to 1.24.
Extending the Treatment Window
The drug’s impact was most notable in patients whose treatment was delayed. While current treatments are highly effective when applied quickly, loberamisal showed its value in patients treated 12–48 hours after symptoms appeared.
Ischaemic strokes occur when a blood vessel supplying oxygen to the brain is blocked. The longer the blockage, the more severe the brain injury. Current treatments focus on removing the blockage as quickly as possible, but this is not always feasible due to delays in seeking help or the complexity of the blockage.
For those with delayed treatment, loberamisal offered a second chance at recovery. Patients receiving the drug were more likely to recover without significant disability compared to those on a placebo.
Trial Design and Results
Led by Dr. Li, the trial followed intention-to-treat principles to ensure practical results. This included data from patients who did not complete the trial, providing a clearer picture of the drug’s effectiveness.
The trial assessed whether loberamisal, given within two days of a stroke, could improve full functional recovery. The primary measure was the modified Rankin scale score, ranging from 0 (no symptoms) to 6 (death).
Patients were randomly assigned to receive either 40 mg of loberamisal or a placebo for 10 consecutive days. After 90 days, researchers evaluated their modified Rankin scale scores.
Read Also: Court Allows Funeral Hall at Miryang Care Hospital
The trial enrolled 998 patients, with 502 in the loberamisal group and 495 in the placebo group. Despite dropouts and protocol deviations, all participants were included in the final analysis.
Results showed loberamisal patients were 12% more likely to achieve a modified Rankin score of 0 or 1 compared to the placebo group. This means 69.7% of loberamisal patients fully recovered, versus 56.3% in the placebo group.
The drug’s safety profile was encouraging, with no significant adverse events reported. Fewer deaths occurred in the loberamisal group compared to the placebo group.
The trial’s success has sparked hopes for further international trials. Dr. Li emphasized the need to confirm the findings in larger, more diverse populations, including patients with more severe strokes and those from different racial and ethnic backgrounds.
Animal studies suggest loberamisal protects neurons from damage caused by NMDAR-mediated excitotoxicity. It also promotes new neuron growth and repairs damaged connections.
Population Considerations
The trial was conducted in China, where stroke is a leading cause of death, often linked to high hypertension rates and potentially genetic factors. Participants had an average BMI of 24, with a quarter in the healthy range for Asian populations.
Dr. Li stressed the need for international trials to confirm efficacy across diverse racial, ethnic, and stroke severity groups. This includes patients with more severe strokes and those who have undergone vascular surgery.
Future Directions
Dr. Li highlighted the importance of studying biomarkers in various population groups to better understand loberamisal’s mechanisms. This research could expand the drug’s applications in global stroke treatment.